Innovation and imitation,opportunity and chall®ε>enge
Asia-Pacific Pharma IP Leader su∏<∞mmit2019---14th-15th NOV, Beijing CHINAOn March 1↓→€9, 2019, the World Intellectual'♦ Property Organization (Wε₽✔IPO) published its global intel₩¥lectual property report 2018.Asian innovators ≈∞♣§filed more than half of their int£$ernational patent applicatε↓φions through WIPO for the first©¶ time in 2018, with significant growth in China≈×$, India and South Korea, σα★the report noted. As a technology-inten&©sive industry, pharmaceutical industry at"±taches great importance to paten•<t application and intellectual property pr↑±α♠otection.In recent y$<≠≥ears, the size of the global ph armaceutical market has maintained a stead↑¥×y growth, with China, South Korea, Indi£↔♣∑a and other emerging markets p↔↓δ∞resenting a rapid growth momentum.±↕δπ Due to the different intellectual proper¶¥ ≥ty policies of different countries, ♠Ωthe strategic layout of g✔≥★lobal intellectual property, the diff☆erences of pharmaceutical intellectual pro£↔>↑perty policies of Asia-pacific ♦★↓λcountries, the patent review processφδ, litigation procedures and Generic dru$↕g patent strategy have gradually become the ↑↑hot spots of the pharmaceutical in<λ tellectual property industry.In this co∑≈±&ntext, the 2019 Asia->™αpacific Pharmaceutical IP Leader Summit will b∏₽'e held in Beijing on November 14-15, an<λ d will attract more than 500 ±↓®industry experts from domestic and foreig≥→n pharmaceutical companies, biotechno¥&'logy companies, governments,♦λ associations, law firms, ¶→σintellectual propert €₽y agents and other companies to attend.Agendaε±₹ Framework:Section 1：Interpretation o♦£♠f Policy: Development of Pharmaceutical IP ∏©$under the New Legislative λ≥Landscape Section 2：Pharmaceutical R&am∑↑p;D Innovation and IP Pr₽±otection -- Global Visi₩δ↕ onSection 3：Case Sharing of Pharmaceutical P♥±atent Invalidity, Infringeme™↑nt, LitigationSection 4：Opportunities and chaδ∑≥llenges for generics companies undeπ®↑r the new situation HOTS≥Ωδ±POT:ü Medical Policy Interpretat∑ <₩ion under the Backgrounφ≈ d of Patent Law Amendmentü The innovation oλ₽&₹f Judicial Mechanism Pro∏↓★γmotes the Development of Pharmaceutical Inte™llectual Propertyü Intell ectual Property Management Experience in Multinat¶∑₩φional Pharmaceutical ↔↕<Companies, Patent Layout Strategyσ , Litigation Strategyü he Data Protectiβ¶β✔on Regulations of Drug Test—New Eraü Tr♣σ₽☆ade Secrets and Patent ≤€ >Layout in the Medical →φ← Fieldü Establishing The Inter ☆nal Intellectual Property System under The New Lε'egislative Landscapeü λ®≠Opportunities and Challenges oγ f Pharmaceutical Enterprises under Patent ★☆↔§Term Compensation System--- Gl₩&φ♥obal Vision and Its Implic®→ations for Chinaü Latest Changes☆♦' in European Patent Application and↑>α Review Proceduresü&n©∞↕bsp; Analysis of Hot Cases of Recent Patent I±©→nvalidationü The Procedure of Am∞λerican Pharmaceutical Patent litigatio✘εn and its Enlightenment to Chines>₩e Pharmaceutical Enterprises Ω↕ ü Application techniques and protect €ion strategies for European ♣'σαand American biomedical patentsü Change♦≠s in standards for creative review of patent≠♦×®sü European, Ameri&↑✔can and Japanese Medical ↓↓Ω←Patent Examination Cases and its implica↑δtions for DomesticPharmaceuti¥∏cal Companiesü Recent Hot Patent In£>××fringement Cases Analysisü The St± rategy of Indian Generic Drug Compa∏'¥nies in R&D and Pre÷'♣-PAü How to avoid the P♥®¶atent Trap in Generic Drug Deβ≈©velopmentü The Stra¶≥±tegy of Generic Drug Companies to Ent∏₽δer the European and American ↓© Marketsü Patentabilit∞₩ y in Europe, the United Stat€es and Chinaü Patent litigation in Eur✘§opeü Doubts arouδ¥&✔nd the Unified Patent Court↑δ (UPC) agreement and Brexitü >€↔★; Second medical use paten&✔tsComposition of participants： Summ$π£it highlights：10+ Hot topic20+¶ε₹ Authoritative speech5 0+ Industry↔₹ media4 0+ BIC110+pharma company↑ >₹ 500+專業(yè)參會(huì)嘉賓 &nbγλsp; &nb₹>≤sp; Professional participantsOfficial registr≥↓≤ation and consultation channels:≠♦'Contact：AnnPhone: 021-65650305Email：Market £ing@zenseegroup.comhttp://en.zenseegroupφ≈★↔.com/p/510934/
